NeoGenomics (NASDAQ:NEO) Raised to Strong-Buy at Zacks Research

NeoGenomics (NASDAQ:NEO) was upgraded by research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report released on Monday,Zacks.com reports.

A number of other equities research analysts have also recently issued reports on NEO. Needham & Company LLC reaffirmed a “buy” rating and issued a $14.00 price objective on shares of NeoGenomics in a research note on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of NeoGenomics in a research report on Monday, December 29th. Leerink Partners set a $14.00 price objective on NeoGenomics in a research note on Tuesday, October 28th. Finally, Cowen restated a “buy” rating on shares of NeoGenomics in a report on Wednesday, January 7th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $12.00.

NeoGenomics Stock Up 3.5%

NEO opened at $12.93 on Monday. The firm has a market capitalization of $1.67 billion, a P/E ratio of -14.69 and a beta of 1.58. NeoGenomics has a one year low of $4.72 and a one year high of $16.18. The company has a fifty day moving average price of $11.68 and a 200-day moving average price of $9.15. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.91 and a quick ratio of 3.62.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings results on Tuesday, October 28th. The medical research company reported $0.03 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.01. NeoGenomics had a negative return on equity of 3.36% and a negative net margin of 16.00%.The firm had revenue of $187.80 million for the quarter, compared to analysts’ expectations of $183.85 million. During the same quarter last year, the firm posted $0.05 EPS. The company’s revenue was up 12.0% compared to the same quarter last year. NeoGenomics has set its FY 2025 guidance at 0.080-0.120 EPS. Equities research analysts expect that NeoGenomics will post -0.2 earnings per share for the current fiscal year.

Insider Buying and Selling at NeoGenomics

In other news, EVP Alicia C. Olivo sold 20,916 shares of the company’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $12.00, for a total value of $250,992.00. Following the sale, the executive vice president directly owned 31,083 shares of the company’s stock, valued at $372,996. This represents a 40.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 2.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On NeoGenomics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Wealth Enhancement Advisory Services LLC purchased a new position in shares of NeoGenomics during the fourth quarter valued at approximately $142,000. Holos Integrated Wealth LLC bought a new position in NeoGenomics during the 4th quarter valued at approximately $76,000. GAMMA Investing LLC raised its stake in NeoGenomics by 68.2% during the fourth quarter. GAMMA Investing LLC now owns 3,602 shares of the medical research company’s stock valued at $42,000 after buying an additional 1,460 shares during the last quarter. CIBC Bancorp USA Inc. purchased a new stake in shares of NeoGenomics in the third quarter worth $106,000. Finally, CANADA LIFE ASSURANCE Co increased its holdings in shares of NeoGenomics by 11.4% during the third quarter. CANADA LIFE ASSURANCE Co now owns 150,140 shares of the medical research company’s stock valued at $1,166,000 after acquiring an additional 15,403 shares in the last quarter. Hedge funds and other institutional investors own 98.50% of the company’s stock.

More NeoGenomics News

Here are the key news stories impacting NeoGenomics this week:

• Positive Sentiment: Preliminary Q4 and FY 2025 revenue above expectations — NeoGenomics reported preliminary Q4 revenue of about $190M and is guiding FY 2025 revenue around $727M, slightly above consensus. Management framed 2025 as a double‑digit revenue growth year, which supports top‑line momentum and the case for future margin improvement. NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue
• Positive Sentiment: New CFO named — NeoGenomics appointed Abhishek Jain as Chief Financial Officer, resolving the CFO transition and reducing near‑term governance uncertainty. Investors typically view a confirmed finance chief as a positive for execution of guidance and investor communications. NeoGenomics Appoints Abhishek Jain to CFO Role
• Positive Sentiment: Analyst support — Needham & Company reaffirmed a Buy rating and set a $14 price target, signaling continued analyst confidence and providing a modest upside reference for investors. Benzinga
• Neutral Sentiment: Short interest update is not meaningful — a January report showed short interest figures that are effectively zero or invalid (NaN) and a 0.0 days‑to‑cover, so there’s no clear short‑squeeze pressure or change in bearish positioning to explain the move. (No external article linked.)

About NeoGenomics

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.